305 related articles for article (PubMed ID: 34509737)
21. Impact of the COVID-19 pandemic on the provision of take-home doses of opioid agonist therapy in Ontario, Canada: A population-based time-series analysis.
Kitchen SA; Campbell TJ; Men S; Bozinoff N; Tadrous M; Antoniou T; Wyman J; Werb D; Munro C; Gomes T
Int J Drug Policy; 2022 May; 103():103644. PubMed ID: 35272107
[TBL] [Abstract][Full Text] [Related]
22. Interest in using buprenorphine-naloxone among a prospective cohort of street-involved young people in Vancouver, Canada.
Pilarinos A; Bingham B; Kwa Y; Joe R; Grant C; Fast D; Buxton JA; DeBeck K
J Subst Use Addict Treat; 2023 May; 148():209005. PubMed ID: 36921770
[TBL] [Abstract][Full Text] [Related]
23. Comparing characteristics and outcomes of different opioid agonist treatment modalities among opioid-dependent federal men correctional populations in Canada.
Farrell MacDonald S; Russell C; Beauchamp T; Derkzen D; Fischer B
Int J Drug Policy; 2022 Feb; 100():103480. PubMed ID: 34656817
[TBL] [Abstract][Full Text] [Related]
24. Treatment retention among patients randomized to buprenorphine/naloxone compared to methadone in a multi-site trial.
Hser YI; Saxon AJ; Huang D; Hasson A; Thomas C; Hillhouse M; Jacobs P; Teruya C; McLaughlin P; Wiest K; Cohen A; Ling W
Addiction; 2014 Jan; 109(1):79-87. PubMed ID: 23961726
[TBL] [Abstract][Full Text] [Related]
25. Buprenorphine/naloxone and methadone effectiveness for reducing craving in individuals with prescription opioid use disorder: Exploratory results from an open-label, pragmatic randomized controlled trial.
McAnulty C; Bastien G; Eugenia Socias M; Bruneau J; Foll BL; Lim R; Brissette S; Ledjiar O; Marsan S; Talbot A; Jutras-Aswad D;
Drug Alcohol Depend; 2022 Oct; 239():109604. PubMed ID: 36037586
[TBL] [Abstract][Full Text] [Related]
26. Enhancing Patient Choice: Using Self-administered Intranasal Naloxone for Novel Rapid Buprenorphine Initiation.
Randall A; Hull I; Martin SA
J Addict Med; 2023 Mar-Apr 01; 17(2):237-240. PubMed ID: 36149001
[TBL] [Abstract][Full Text] [Related]
27. Concomitant Heroin and Cocaine Use among Opioid-Dependent Patients during Methadone, Buprenorphine or Morphine Opioid Agonist Therapy.
Gastberger S; Baumgartner MR; Soyka M; Quednow BB; Hulka LM; Herdener M; Seifritz E; Mutschler J
Eur Addict Res; 2019; 25(4):207-212. PubMed ID: 31067528
[TBL] [Abstract][Full Text] [Related]
28. A population-based time-series analysis of opioid agonist treatment dispensed during pregnancy.
Schmidt RA; Everett K; Perez-Brumer A; Strike C; Rush B; Gomes T
Addiction; 2024 Jun; 119(6):1111-1122. PubMed ID: 38476027
[TBL] [Abstract][Full Text] [Related]
29. Does opioid agonist treatment reduce overdose mortality risk in people who are older or have physical comorbidities? Cohort study using linked administrative health data in New South Wales, Australia, 2002-17.
Larney S; Jones NR; Hickman M; Nielsen S; Ali R; Degenhardt L
Addiction; 2023 Aug; 118(8):1527-1539. PubMed ID: 36843415
[TBL] [Abstract][Full Text] [Related]
30. Buprenorphine/naloxone as a promising therapeutic option for opioid abusing patients with chronic pain: reduction of pain, opioid withdrawal symptoms, and abuse liability of oral oxycodone.
Roux P; Sullivan MA; Cohen J; Fugon L; Jones JD; Vosburg SK; Cooper ZD; Manubay JM; Mogali S; Comer SD
Pain; 2013 Aug; 154(8):1442-8. PubMed ID: 23707283
[TBL] [Abstract][Full Text] [Related]
31. Long-term follow-up assessment of opioid use outcomes among individuals with comorbid mental disorders and opioid use disorder treated with buprenorphine or methadone in a randomized clinical trial.
Hser YI; Zhu Y; Fei Z; Mooney LJ; Evans EA; Kelleghan A; Matthews A; Yoo C; Saxon AJ
Addiction; 2022 Jan; 117(1):151-161. PubMed ID: 34105213
[TBL] [Abstract][Full Text] [Related]
32. The OPTIMA study, buprenorphine/naloxone and methadone models of care for the treatment of prescription opioid use disorder: Study design and rationale.
Socias ME; Ahamad K; Le Foll B; Lim R; Bruneau J; Fischer B; Wild TC; Wood E; Jutras-Aswad D
Contemp Clin Trials; 2018 Jun; 69():21-27. PubMed ID: 29627621
[TBL] [Abstract][Full Text] [Related]
33. Treatment retention in opioid agonist therapy: comparison of methadone versus buprenorphine/naloxone by analysis of daily-witnessed dispensed medication in a Canadian Province.
Sadek J; Saunders J
BMC Psychiatry; 2022 Jul; 22(1):516. PubMed ID: 35908052
[TBL] [Abstract][Full Text] [Related]
34. Flexible Buprenorphine/Naloxone Model of Care for Reducing Opioid Use in Individuals With Prescription-Type Opioid Use Disorder: An Open-Label, Pragmatic, Noninferiority Randomized Controlled Trial.
Jutras-Aswad D; Le Foll B; Ahamad K; Lim R; Bruneau J; Fischer B; Rehm J; Wild TC; Wood E; Brissette S; Gagnon L; Fikowski J; Ledjiar O; Masse B; Socias ME;
Am J Psychiatry; 2022 Oct; 179(10):726-739. PubMed ID: 35702828
[TBL] [Abstract][Full Text] [Related]
35. Association Between Increased Dispensing of Opioid Agonist Therapy Take-Home Doses and Opioid Overdose and Treatment Interruption and Discontinuation.
Gomes T; Campbell TJ; Kitchen SA; Garg R; Bozinoff N; Men S; Tadrous M; Munro C; Antoniou T; Werb D; Wyman J
JAMA; 2022 Mar; 327(9):846-855. PubMed ID: 35230394
[TBL] [Abstract][Full Text] [Related]
36. Trends in engagement in the cascade of care for opioid use disorder, Vancouver, Canada, 2006-2016.
Socías ME; Wood E; Kerr T; Nolan S; Hayashi K; Nosova E; Montaner J; Milloy MJ
Drug Alcohol Depend; 2018 Aug; 189():90-95. PubMed ID: 29894910
[TBL] [Abstract][Full Text] [Related]
37. Cannabis use is associated with reduced risk of exposure to fentanyl among people on opioid agonist therapy during a community-wide overdose crisis.
Socías ME; Choi J; Lake S; Wood E; Valleriani J; Hayashi K; Kerr T; Milloy MJ
Drug Alcohol Depend; 2021 Feb; 219():108420. PubMed ID: 33342591
[TBL] [Abstract][Full Text] [Related]
38. Impact of Emergency Department-Initiated Buprenorphine on Repeat Emergency Department Utilization.
Skains RM; Reynolds L; Carlisle N; Heath S; Covington W; Hornbuckle K; Walter L
West J Emerg Med; 2023 Nov; 24(6):1010-1017. PubMed ID: 38165181
[TBL] [Abstract][Full Text] [Related]
39. Does the Addition of Naloxone in Buprenorphine/Naloxone Affect Retention in Treatment in Opioid Replacement Therapy?: A Systematic Review and Meta-Analysis.
Dalton K; Butt N
J Addict Nurs; 2019; 30(4):254-260. PubMed ID: 31800516
[TBL] [Abstract][Full Text] [Related]
40. Opioid agonist treatment and risk of mortality during opioid overdose public health emergency: population based retrospective cohort study.
Pearce LA; Min JE; Piske M; Zhou H; Homayra F; Slaunwhite A; Irvine M; McGowan G; Nosyk B
BMJ; 2020 Mar; 368():m772. PubMed ID: 32234712
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]